ENFLONSIA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
ENFLONSIA
Date registered
Evaluation commenced
Decision date
Approval time
171 (255 working days)
Active ingredients
clesrovimab
Registration type
NCE/NBE
Indication
ENFLONSIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
ENFLONSIA should be used in accordance with official recommendations.